CoChat

Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study

Open access
Boccardi, Marina, Altomare, Daniele, Ferrari, Clarissa, Festari, Cristina, Guerra, Ugo Paolo, Paghera, Barbara, Pizzocaro, Claudio, Lussignoli, Giulia, Geroldi, Cristina, Zanetti, Orazio, Cotelli, Maria Sofia, Turla, Marinella, Borroni, Barbara, Rozzini, Luca, Mirabile, Dario, Defanti, Carlo, Gennuso, Michele, Prelle, Alessandro, Gentile, Simona, Morandi, Alessandro, Vollaro, Stefano, Volta, Giorgio Dalla, Bianchetti, Angelo, Conti, Marta Zaffira, Cappuccio, Melania, Carbone, Pasqualina, Bellandi, Daniele, Abruzzi, Luciano, Bettoni, Luigi, Villani, Daniele, Raimondi, Maria Clara, Lanari, Alessia, Ciccone, Alfonso, Facchi, Emanuela, Di Fazio, Ignazio, Rozzini, Renzo, Boffelli, Stefano, Manzoni, Laura, Salvi, Giovanni Pietro, Cavaliere, Sabina, Belotti, Gloria, Avanzi, Stefano, Pasqualetti, Patrizio, Muscio, Cristina, Padovani, Alessandro, Frisoni, Giovanni B., for the Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Working Group · 2016 · JAMA Neurology
Cited by 94

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

IMPORTANCE: Cerebral amyloidosis is a key abnormality in Alzheimer disease (AD) and can be detected in vivo with positron emission tomography (PET) ligands. Although amyloid PET has clearly demonstrated analytical validity, its clinical utility is debated. OBJECTIVE: To evaluate the incremental diagnostic value of amyloid PET with florbetapir F 18 in addition to the routine clinical diagnostic assessment of patients evaluated for cognitive impairment. DESIGN, SETTING, AND PARTICIPANTS: The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study is a multicenter study involving 18 AD evaluation units from eastern Lombardy, Northern Italy, 228 consecutive adults with cognitive impairment were evaluated for AD and other causes of cognitive decline, with a prescan diagnostic confidence of AD between 15% and 85%. Participants underwent routine clinical and instrumental diagnostic assessment. A prescan diagnosis was made, diagnostic confidence was estimated, and drug treatment was provided. At the time of this workup, an amyloid PET/computed tomographic scan was performed, and the result was communicated to physicians after workup completion. Physicians were asked to review the diagnosis, diagnostic confidence, and treatment after the scan. The study was conducted from August 5, 2013, to December 31, 2014. MAIN OUTCOMES AND MEASURES: Primary outcomes were prescan to postscan changes of diagnosis, diagnostic confidence, and treatment. RESULTS: Of the 228 participants, 107 (46%) were male; mean (SD) age was 70.5 (7) years. Diagnostic change occurred in 46 patients (79%) having both a previous diagnosis of AD and an amyloid-negative scan (P < .001) and in 16 (53%) of those with non-AD diagnoses and an amyloid-positive scan (P < .001). Diagnostic confidence in AD diagnosis increased by 15.2% in amyloid-positive (P < .001; effect size Cohen d = 1.04) and decreased by 29.9% in amyloid-negative (P < .001; d = -1.19) scans. Acetylcholinesterase inhibitors and memantine hydrochloride were introduced in 61 (65.6%) patients with positive scan results who had not previously received those drugs, and the use of the drugs was discontinued in 6 (33.3%) patients with negative scan results who were receiving those drugs (P < .001). CONCLUSIONS AND RELEVANCE: Amyloid PET in addition to routine assessment in patients with cognitive impairment has a significant effect on diagnosis, diagnostic confidence, and drug treatment. The effect on health outcomes, such as morbidity and mortality, remains to be assessed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaneurol.2016.3751

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 94

Metadata

Authors
Boccardi, M., Altomare, D., Ferrari, C., Festari, C., Guerra, U. P., Paghera, B., Pizzocaro, C., Lussignoli, G., Geroldi, C., Zanetti, O., Cotelli, M. S., Turla, M., Borroni, B., Rozzini, L., Mirabile, D., Defanti, C., Gennuso, M., Prelle, A., Gentile, S., Morandi, A., Vollaro, S., Volta, G. D., Bianchetti, A., Conti, M. Z., Cappuccio, M., Carbone, P., Bellandi, D., Abruzzi, L., Bettoni, L., Villani, D., Raimondi, M. C., Lanari, A., Ciccone, A., Facchi, E., Di Fazio, I., Rozzini, R., Boffelli, S., Manzoni, L., Salvi, G. P., Cavaliere, S., Belotti, G., Avanzi, S., Pasqualetti, P., Muscio, C., Padovani, A., Frisoni, G. B., & for the Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Working Group
Venue
JAMA Neurology
Published
2016-12-01
Volume
73
Issue
12
Pages
1417
ISSN
2168-6149 (ISSN-L)
OpenAlex
W2545072337
Cited by
94
References
14
FWCI
10.87
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study. https://app.cochat.ai/papers/10.1001/jamaneurol.2016.3751
The paper
Boccardi, M., Altomare, D., Ferrari, C., Festari, C., Guerra, U. P., Paghera, B., Pizzocaro, C., Lussignoli, G., Geroldi, C., Zanetti, O., Cotelli, M. S., Turla, M., Borroni, B., Rozzini, L., Mirabile, D., Defanti, C., Gennuso, M., Prelle, A., Gentile, S., . . . for the Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Working Group. (2016). Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2016.3751

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.